ArticleScientific reports2026
Association of immune-related adverse events with survival in patients receiving immune checkpoint inhibitor plus chemotherapy for lung cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
The association of immune-related adverse events (irAEs) and baseline peripheral blood count ratios with the effectiveness of immune checkpoint inhibitor (ICI) plus chemotherapy in patients with non-small cell lung cancer (NSCLC) remains unclear. This multicenter, retrospective study analyzed data from 191 patients treated with pembrolizumab or atezolizumab plus chemotherapy as first-line therapy across five hospitals in Japan between December 2018 and March 2021. Progression-free survival (PFS) and overall survival (OS) were assessed in relation to irAEs within a 6-week landmark analysis and baseline peripheral blood count ratios using Cox proportional hazards models. IrAEs occurred in 70 patients (36.6%) and showed no substantial association with survival (PFS: hazard ratio [HR] = 1.04, 95% confidence interval [CI] = 0.70–1.53 and OS: HR = 0.82, 95% CI = 0.49–1.34). Conversely, baseline peripheral blood count ratios were considerably linked to survival. A higher neutrophil-to-lymphocyte ratio correlated with reduced PFS (adjusted HR = 1.62, 95% CI = 1.10–2.40) and OS (adjusted HR = 2.50, 95% CI = 1.53–4.09), with similar trends for the lymphocyte-to-monocyte and platelet-to-lymphocyte ratios. Collectively, these findings suggest that although irAEs were not predictive of survival, baseline blood count ratios can serve as prognostic biomarkers in patients with NSCLC receiving chemoimmunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.